Ethyl linoleate

Ethyl Linoleate: A Comprehensive Reference

1. Identity and Chemical Characterization

Chemical Names and Identifiers

Ethyl linoleate is a long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of linoleic acid with the hydroxy group of ethanol. It is most commonly referred to by its IUPAC name ethyl (9Z,12Z)-octadeca-9,12-dienoate, but is encountered under numerous synonyms in the scientific and commercial literature:

• Linoleic acid ethyl ester (the most frequently used alternative name)
• 9,12-Octadecadienoic acid (Z,Z)-, ethyl ester
• Ethyl cis,cis-9,12-octadecadienoate
• Mandenol
• Vitamin F ethyl ester (a historical trade designation)
• Synovea® EL (a current cosmetic trade name)

The CAS Registry Number is 544-35-4, and the EC number is 208-868-4. From the molecular ion signal of ethyl linoleate at m/z 308, an elemental composition of C₂₀H₃₆O₂ was ascertained. The compound belongs to the chemical class of fatty acid ethyl esters (FAEEs), a subgroup of fatty acid alkyl esters. According to ChEBI, ethyl linoleate has a role as a plant metabolite and an anti-inflammatory agent.

Structural Features

Ethyl linoleate (linoleic acid ethyl ester) is an unsaturated fatty acid resulting from formal condensation of the carboxyl group of linoleic acid with the hydroxyl group of ethanol. The molecule retains the two characteristic cis-configured double bonds at the Δ9 and Δ12 positions (methylene-interrupted polyene) that define the parent linoleic acid (C18:2, n-6). The ethyl ester at the carboxyl terminus distinguishes it from the free acid form and from its methyl ester analogue. Ethyl linoleate (sometimes referred to as vitamin F) is classified as an emollient and an essential fatty acid ester.

Natural Occurrence and Botanical Sources

Ethyl linoleate occurs naturally in a range of plants, often detectable in essential oil fractions and non-polar extracts. Key documented plant sources include:

• Garlic (Allium sativum): Ethyl linoleate (ELA) was isolated from the cloves of Allium sativum, and its structure was elucidated by NMR and GC-MS analyses.
• Black wolfberry (Lycium ruthenicum): Water-distilled essential oils from the fruits of Lycium ruthenicum were analyzed by GC-MS; the essential oil of L. ruthenicum has heptacosane (14.3%), ethyl linoleate (10.0%), hexacosane (7.0%), nonacosane (6.2%), and ethyl hexadecanoate (5.8%) as the main compounds.
• Purple shamrock (Oxalis triangularis): EL was isolated from Oxalis triangularis (purple shamrock or clover), an edible perennial plant that can easily be cultivated. Ten fatty acid alkyl esters isolated from Oxalis triangularis were evaluated for effects on melanogenesis; treatment with ethyl linoleate, among others, significantly blocked forskolin-induced melanogenesis and inhibited tyrosinase activity.
• Foxtail millet bran (Setaria italica): Foxtail millet (Setaria italica) bran oil is rich in linoleic acid, which accounts for more than 60% of its lipids, and ethyl linoleate is obtainable from this bran oil.

The presence of naturally occurring fatty acid methyl esters (FAMEs) and related alkyl esters has been reported previously in plants and microalgae. Beyond direct occurrence, ethyl linoleate can also be produced endogenously in biological matrices when fatty acid esterification occurs in the presence of ethanol—a phenomenon relevant to metabolomics research. Research includes the use of ethyl linoleate in the study of liver metabolomics to understand the biochemical effects of alcohol dosing; ethyl linoleate's role in nonpolar metabolite profiling provides insights into liver function and the metabolic impacts of alcohol consumption.

Common Forms and Preparations

Ethyl linoleate is encountered in the following principal forms in research and commercial contexts:

• Neat liquid (≥99% purity by GC): Used in laboratory research as a reference standard or reagent.
• Topical lotion/emulsion: Applied to the skin in formulated products, most notably in acne and skin-brightening products. Concentrations tested clinically include 3% HREL (hexylresorcinol-ethyl linoleate) lotion.
• Self-microemulsifying drug delivery systems (SMEDDS): Ethyl linoleate has been utilized in a self-microemulsifying drug delivery system to enhance the bioavailability of silymarin; the study showed improved absorption and bioavailability of silymarin.
• Purified food-grade preparations from bran oil: ELA processing steps of urea complexation (UC) and molecular distillation (MD) have been used to obtain highly concentrated ELA at levels permitted by current regulations.
• Dietary supplement / health food ingredient: ELA can be added to health food because of its function of reducing cholesterol and blood lipid levels.

2. Traditional and Historical Use

Ethyl linoleate as an isolated, chemically defined compound does not have a long documented history of traditional use. Rather, its traditional background is inseparable from that of its parent molecule, linoleic acid, and the linoleic acid-rich plant oils from which it is derived.

While ethyl linoleate itself is a refined compound, its parent molecule, linoleic acid, has been valued for centuries in herbal medicine and nutritional therapies. Ancient cultures used linoleic acid-rich plant oils—such as safflower, sunflower, and evening primrose oil—for skin conditions, wound healing, and to support general wellness; these oils were often incorporated into topical balms, ointments, and dietary preparations, aiming to harness their soothing and restorative properties.

Garlic (Allium sativum), one of the confirmed botanical sources of naturally occurring ethyl linoleate, has a history of medicinal use stretching back thousands of years across multiple civilisations—including ancient Egyptian, Greek, Roman, Chinese, and Indian (Ayurvedic) traditions—where it was applied internally and externally for infections, cardiovascular support, and wound healing. The biological effects of garlic constituents have been reported for several decades; several of these biological effects are associated with the thiosulfinates and volatile sulfur compounds present in garlic. These compounds are unstable and give rise to transformation products; for this reason, recent attention has been focused on polar compounds that are more stable upon cooking and in storage. It is within this context of investigating the stable, non-sulfur constituents of garlic that ethyl linoleate was eventually isolated and characterized.

Foxtail millet (Setaria italica), another documented botanical source, has a long history in East Asian traditional diets. Foxtail millet is one of the world's oldest cultivated crops. Its use as a nutritional staple, and its association with health maintenance in traditional Chinese medicine, predates formal knowledge of its fatty acid ester constituents. However, the specific attribution of health effects to ethyl linoleate isolated from this plant is a product of modern analytical chemistry rather than classical ethnobotanical designation.

With scientific advancements, ethyl linoleate became notable for its improved bioavailability and stability compared to pure linoleic acid. The deliberate use of ethyl linoleate as a specific ingredient—rather than as a component of unfractionated plant oils—therefore belongs primarily to the modern era of cosmetic chemistry, nutraceutical science, and pharmaceutical research, rather than to traditional herbal medicine per se.

3. Key Constituents and Established Mechanisms of Action

The Core Molecule: Relationship to Linoleic Acid

Ethyl linoleate is the ethyl ester of linoleic acid, an essential omega-6 fatty acid that plays a crucial role in human health. Linoleic acid (C18:2, n-6) is itself an essential fatty acid that humans cannot synthesize de novo and must obtain through diet. Upon metabolic hydrolysis of the ester bond, ethyl linoleate liberates free linoleic acid, which can subsequently enter the n-6 PUFA elongation-desaturation pathway to produce arachidonic acid (C20:4, n-6) and other downstream eicosanoids.

The conversion of linoleic to arachidonic acid is not hindered by dietary triglycerides of saturated fatty acids; levels of 20:4ω6 were in fact higher in rats fed triglycerides of saturated fatty acids alongside ethyl linoleate supplementation than in rats fed linoleic acid only.

Anti-Inflammatory Mechanisms

Multiple intersecting molecular pathways underpin ethyl linoleate's anti-inflammatory activity:

• iNOS and COX-2 downregulation: ELA down-regulates inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression, thereby reducing nitric oxide (NO) and prostaglandin E2 production in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages.
• NF-κB and MAPK pathway inhibition: Ethyl linoleate inhibits the Akt/GSK3β/β-catenin signaling pathway and the activation of NF-κB. ELA suppressed inducible nitric oxide synthase (iNOS) formed as a result of LPS treatment; in RAW 264.7 cells, ELA-triggered heme oxygenase-1 (HO-1) regulates the reduction of LPS-induced NO and pro-inflammatory cytokine synthesis.
• HO-1 induction: Ethyl linoleate induces heme oxygenase-1 (HO-1). HO-1 is a cytoprotective enzyme that degrades pro-oxidant heme and generates carbon monoxide, biliverdin, and bilirubin—all of which exert anti-inflammatory and antioxidant effects. The induction of HO-1 by ELA represents a mechanistically distinct anti-inflammatory strategy compared to direct enzyme inhibition.
• Reactive oxygen species (ROS) suppression: ELA inhibits the action of reactive species of oxygen released by neutrophils due to an excess of bacteria, and prevents the hyperkeratinization induced by a lack of linoleic acid.

Anti-Melanogenic Mechanisms

The depigmenting activity of ethyl linoleate operates through regulation of the melanogenesis signaling cascade rather than through direct, competitive inhibition of the tyrosinase enzyme:

• MITF, tyrosinase, and TRP-1 suppression: Ethyl linoleate inhibited the expression of microphthalmia-associated transcription factor (MITF), tyrosinase, and tyrosinase related protein 1 (TRP1) in governing melanin pigment synthesis.
• Akt/GSK3β/β-catenin pathway: Ethyl linoleate inhibited phosphorylation of Akt and glycogen synthase kinase 3β (GSK3β) and reduced the level of β-catenin, suggesting that ethyl linoleate inhibits melanogenesis through the Akt/GSK3β/β-catenin signal pathway.
• cAMP suppression: Ethyl linoleate isolated from Oxalis triangularis inhibits forskolin-induced melanogenesis and tyrosinase activity in mouse B16 melanoma cells; this anti-melanogenic effect is mediated by inhibiting cAMP production.

Cardiovascular and Lipid Metabolism Effects

ELA has many physiological functions, such as enhancing immunity, reducing cholesterol and blood lipid levels, and mediating and controlling metabolism. In experimental models, the compound has been shown to influence aortic integrity and plasma lipids (see Section 4 below).

Drug Delivery and Absorption Enhancement

Ethyl linoleate promotes compound absorption. Its lipophilic character and capacity to disrupt lipid barriers make it a useful excipient in self-microemulsifying drug delivery systems, enhancing the oral and/or transdermal bioavailability of poorly soluble co-administered compounds.

4. Scientific Evidence by Area of Use

4.1 Acne Vulgaris (Topical)

The most clinically substantiated application of ethyl linoleate is its topical use for acne vulgaris, where it has been tested in combination with triethyl citrate.

Randomized Controlled Trial (RCT): A double-blind, placebo-controlled, randomized study was conducted to evaluate the efficacy and tolerability of a novel lotion containing triethyl citrate and ethyl linoleate in the treatment of mild to moderate acne vulgaris; it compared the active lotion with its vehicle as a placebo control. Patients were assessed by the modified Leeds acne grading system as well as by counting inflammatory and noninflammatory lesions on the face at weeks 0, 4, 8, and 12. Key findings included:

• Active treatment was statistically superior to placebo in reduction of Leeds grading and total, inflammatory, and noninflammatory lesion counts.
• The active lotion showed a rapid response with obvious reduction in lesion counts and acne grading by 4 weeks.
• Sebum production was significantly reduced in the actively treated group, with a mean reduction of 53% in sebum production compared with baseline.
• One patient developed irritation to the active lotion and withdrew from the study; the new lotion containing triethyl citrate and ethyl linoleate was shown to be an effective treatment for mild to moderate acne, with an effect on both inflammatory and noninflammatory acne lesions, and worked quickly and was generally well tolerated.

Hexylresorcinol-Ethyl Linoleate (HREL) Pilot Study: An anti-acne clinical study of 10 subjects (ages 21.30 ± 4.54, five male and five female, Fitzpatrick Types II–IV, all with mild acne) applied a 3% HREL lotion twice daily for six weeks. After six weeks of treatment, subjects experienced significantly reduced inflammatory and non-inflammatory acne lesions, post-inflammatory hyperpigmentation (PIH), and average pore diameters and pore counts, as well as overall improvements to skin texture and appearance; significant reductions in erythema were also observed, with no evidence of worsening in any tolerance attributes compared with baseline. HREL was found to be more effective in inhibiting transcriptional regulatory activity of NF-κB, compared with known inhibitors curcumin and resveratrol. Evidence strength note: This was a small, uncontrolled, open-label pilot study (n=10) and should be interpreted with caution; it is hypothesis-generating rather than confirmatory.

The proposed mechanism in the context of acne involves multiple pathways: ethyl linoleate decreases sebaceous gland activity, regulating excess oil production, which helps minimize acne; it also regulates follicular keratinization, a major pathogenic factor of acne, and produces anti-inflammatory effects by inhibiting NF-κB, a pro-inflammatory transcription factor.

4.2 Skin Hyperpigmentation and Melanogenesis (In Vitro)

Ethyl linoleate is used in many cosmetics for its antibacterial and anti-inflammatory properties; in studies using B16F10 murine melanoma cells, it significantly inhibited melanin content and intracellular tyrosinase activity in α-MSH-induced cells, but did not directly inhibit activity of mushroom tyrosinase. Ethyl linoleate inhibited the expression of microphthalmia-associated transcription factor (MITF), tyrosinase, and tyrosinase related protein 1 (TRP1) in governing melanin pigment synthesis.

Free fatty acids have regulatory effects on melanogenesis; unsaturated fatty acids such as oleic acid (C18:1), linoleic acid (C18:2), and α-linolenic acid (C18:3) suppress melanin synthesis and tyrosinase activity, whereas saturated fatty acids such as palmitic acid (C16:0) and stearic acid (C18:0) induce melanin synthesis.

Based on these in vitro results, ethyl linoleate was proposed as a potentially safe whitening agent in cosmetics and a potential therapeutic agent for reducing skin hyperpigmentation.

Evidence strength note: All melanogenesis data currently derive from cell-culture experiments (murine B16F10 melanoma cells and human dermal fibroblasts). There are no published randomized clinical trials specifically evaluating ethyl linoleate monotherapy for hyperpigmentation in humans. Evidence at this stage is preliminary and mechanism-defining only.

4.3 Anti-Inflammatory Activity (In Vitro / Animal)

In vitro systems were used to evaluate the anti-inflammatory activity of ELA; results indicate that ELA down-regulates inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression and thereby reduces nitric oxide (NO) and prostaglandin E2 production in lipopolysaccharide (LPS)-activated RAW 264.7 cells.

These findings established the anti-inflammatory effects of ELA, suggesting it could be employed as a medical therapy to treat inflammation-related disorders.

Evidence strength note: All dedicated anti-inflammatory mechanistic studies for ethyl linoleate have used cell-culture (RAW264.7 macrophage) models. These are valuable for elucidating mechanisms but cannot substitute for clinical trial data. No dedicated human clinical trials examining systemic anti-inflammatory effects of ethyl linoleate have been published.

4.4 Rheumatoid Arthritis (In Vitro / Animal Network Pharmacology)

A 2025 study investigated the mechanisms through which Jinwu Jiangu Capsules (JJC), a traditional Chinese medicine formulation, ameliorate rheumatoid arthritis (RA). The study investigated how monomers of JJC regulate the DKK1/Wnt-OPG signaling axis and autophagy in RA, both in vivo and in vitro, and evaluated anti-arthritis effects using a Type II collagen-induced arthritis (CIA) rat model. JJC effectively reduced the expression of DKK1, RANKL, β-catenin, and p-β-catenin while increasing the levels of autophagy-related proteins such as Beclin-1, LC3, and Atg5; network pharmacology analysis revealed that ethyl linoleate (EL), a key component of JJC, targeted DKK1.

Evidence strength note: This represents network pharmacology (computational target identification) combined with in vitro and animal work. Ethyl linoleate's specific contribution within the multi-component formulation has not been isolated in a controlled human trial. Evidence for anti-arthritic effects is preliminary and indirect.

4.5 Cardiovascular / Atherosclerosis (Animal Models)

Some of the earliest published research on ethyl linoleate focused on its potential anti-atherogenic properties in animal models.

Aortic degeneration, evidenced by lipid infiltration of the intima, was observed in control groups but not in linoleate-fed groups; groups that received butterfat or hydrogenated coconut oil showed reduced plasma and hepatic cholesterol levels when fed 2% of ethyl linoleate, while groups that received a fat-free diet with 2% of ethyl linoleate showed lower plasma and hepatic cholesterol levels and more complete aortic protection than groups fed 20% of corn oil or cottonseed oil. The data suggest that, in the cholesterol-fed rat, the kind and amount of dietary fatty esters may influence aortic condition via some route(s) other than control of plasma and hepatic cholesterol levels.

Chinese yam extracts containing both β-sitosterol and ethyl linoleate have been studied in the context of atherosclerosis: extracts containing β-sitosterol and ethyl linoleate were shown to protect against atherosclerosis in apolipoprotein E-deficient mice and inhibit muscular expression of VCAM-1 in vitro.

Ethyl linoleate is also cited as the raw material for producing a drug that is highly effective at preventing and treating chronic diseases such as cerebral thrombosis and atherosclerosis.

Evidence strength note: Cardiovascular data derive entirely from rodent models and, in some cases, mixed-extract preparations (not pure ELA). Early PubMed-indexed work on the topic (1965–1968) lacks accessible abstracts and used rabbit and rat models. There is currently no published randomized clinical trial examining ethyl linoleate alone for cardiovascular endpoints in humans.

4.6 Essential Fatty Acid Delivery and Prostaglandin Metabolism (Animal)

Ethyl linoleate has been used extensively as a research tool for studying essential fatty acid (EFA) deficiency and the influence of dietary n-6 fatty acid supply on eicosanoid metabolism.

Three groups of weanling male rats were reared on a fat-free diet for 13 weeks; one group received only the fat-free diet, and another received the fat-free diet with a daily supplement of 2 energy% ethyl linoleate (n-6 rats). The release of PGE2-like activity expressed as ng PGE2-equivalent per g lung tissue was 65 ± 20 for the n-6 (ethyl linoleate-supplemented) rats, substantially higher than the fat-free controls. This illustrates that dietary ethyl linoleate efficiently serves as a precursor to arachidonic acid-derived eicosanoids, replicating the metabolic role of linoleic acid.

In a separate study examining saturated fatty acid interactions with linoleate metabolism, all groups were given a daily oral supplement of ethyl linoleate at a level of 0.5% of total calories. The conversion of linoleic to arachidonic acid was not hindered by the dietary triglycerides of saturated fatty acids.

4.7 Skin Barrier Function and Acne Pathophysiology

Linoleic acid deficiency in the skin is a documented pathogenic factor in acne, as the ceramide-forming linoleate is depleted from sebum and the follicular epithelium. ELA prevents the hyperkeratinization induced by a lack of linoleic acid. The use of ethyl linoleate as a topical linoleic acid surrogate exploits its greater oxidative stability compared to the free acid form while still permitting enzymatic (lipase/esterase) hydrolysis at the skin surface to release active linoleic acid. EL is more stable to oxidation than linoleic acid (LA), as was shown by decreased amounts of it on the skin surface lipids of subjects treated for acne.

5. Body Systems and Health Areas Associated with Ethyl Linoleate

• Integumentary system (skin): Acne vulgaris management (topical, including sebum reduction and follicular keratinization regulation); skin hyperpigmentation and melanogenesis modulation; skin barrier maintenance and emolliency. Its potential role in skin barrier enhancement and repair has been observed, making it a valued ingredient in both nutritional and topical formulations.
• Immune and inflammatory system: Macrophage-mediated inflammation modulation via NF-κB, MAPK, and HO-1 pathways. Ethyl linoleate is used in the research of inflammatory diseases.
• Musculoskeletal system: Exploratory research in rheumatoid arthritis models via DKK1/Wnt-OPG axis and autophagy modulation.
• Cardiovascular system: Anti-atherogenic activity and lipid-lowering effects documented in rodent models. Ethyl linoleate has a significant influence on atherosclerosis.
• Hepatic / lipid metabolism: Roles in cholesterol and blood lipid metabolism, as well as liver metabolomics research related to alcohol-associated fatty acid profiling.
• Drug delivery: Use as a lipid excipient in SMEDDS formulations to enhance oral bioavailability of poorly soluble drugs.

6. Dosage Forms and Dosages Reported in Studies

Topical Formulations

• Triethyl citrate + ethyl linoleate lotion (RCT, BJD 2007): A lotion containing triethyl citrate and ethyl linoleate was applied topically for mild to moderate acne vulgaris; the study was a double-blind, placebo-controlled, randomized trial with assessments at weeks 0, 4, 8, and 12. Specific percentage concentrations were not provided in the abstract.
• 3% HREL (hexylresorcinol-ethyl linoleate) lotion: Subjects applied a 3% HREL lotion twice daily for six weeks.
• In vitro cytotoxicity concentration: To examine cell safety of ethyl linoleate, B16F10 murine melanoma and human dermal fibroblast cells were treated with various concentrations of ethyl linoleate; ethyl linoleate revealed no significant cytotoxic effect on both cell types at a concentration of 400 µM, and 400 µM ethyl linoleate was used for further experiments.

Oral / Dietary Dosages in Animal Research

• A supplement of 2 energy% ethyl linoleate was used in a 13-week rat study of essential fatty acid supply and prostaglandin metabolism.
• A daily oral supplement of ethyl linoleate at a level of 0.5% of total calories was used in a rat study of saturated fatty acid interactions with linoleate metabolism over 80 days.
• Groups that received butterfat or hydrogenated coconut oil showed reduced plasma and hepatic cholesterol levels when fed 2% of ethyl linoleate in an atherosclerosis rat model.
• The reference dose of DB extract used in one anti-atherosclerosis study was 200 mg/kg, with ethyl linoleate accounting for 43.2%; therefore, the dose of ethyl linoleate in that study was 86.4 mg/kg.

No established human oral supplementation dosage for ethyl linoleate has been defined in peer-reviewed clinical trials. The animal dosages above are provided solely as context for the research record and are not indicative of human dosing recommendations.

7. Safety Considerations and Interactions

General Tolerability from Clinical Data

The lotion containing triethyl citrate and ethyl linoleate was shown to be an effective treatment for mild to moderate acne and was generally well tolerated. One patient developed irritation to the active lotion and withdrew from the study.

Objective assessments of skin tolerance including dryness, erythema, and edema, and subjective assessments of stinging, itching, tingling, and burning all indicated the formula was well-tolerated.

In Vitro Cytotoxicity Profile

Cytotoxicity of a drug is critical if it is used either as a cosmetic or a medicine agent; to examine the cell safety of ethyl linoleate, B16F10 murine melanoma and human dermal fibroblast cells were treated with various concentrations of ethyl linoleate, and ethyl linoleate revealed no significant cytotoxic effect on both cell types at a concentration of 400 µM.

Antibiotic-Resistance Advantage (Acne Context)

Triethyl citrate/ethyl linoleate (TCEL) displays hopeful qualities for acne therapy; it minimizes skin lesions promptly while causing few adverse reactions and low likelihood of resurgence, and, contrasting with antibiotics, TCEL averts promoting bacterial resistance. This is a clinically relevant safety advantage given the growing concern about antibiotic resistance in dermatology.

Oxidative Stability as a Safety Consideration

EL is more stable to oxidation than linoleic acid (LA), as was shown by decreased amounts of it on the skin surface lipids of subjects treated for acne; these facts suggest EL could provide benefits similar to LA with the advantage of improved stability. The reduced susceptibility to peroxidation relative to the free polyunsaturated acid diminishes the theoretical concern about lipid peroxide formation at the site of application, though this has not been evaluated systematically in long-term clinical studies.

Metabolic Hydrolysis and Prodrug Behavior

Ethyl linoleate behaves as a prodrug upon application to or ingestion by biological systems: skin-resident lipases and esterases cleave the ethyl ester bond, releasing free linoleic acid and ethanol. The liberated ethanol at typical topical application concentrations is negligible in systemic terms but represents the active conversion step for pharmacological activity. This hydrolysis-dependent mechanism means that the safety profile of absorbed ELA is closely linked to that of linoleic acid itself.

Absence of Long-Term Human Safety Data

Despite promising findings, comprehensive clinical studies in humans remain limited; while preliminary research indicates that ethyl linoleate can be efficiently metabolized and utilized by the body, more robust, large-scale trials are needed to fully validate its efficacy and safety in nutritional applications. Long-term systemic supplementation studies specifically examining ethyl linoleate have not been published in the accessible peer-reviewed literature.

Potential Drug Interactions (Theoretical, Based on Mechanism)

Given ethyl linoleate's documented inhibition of NF-κB and COX-2 pathways, theoretical pharmacodynamic overlap with anti-inflammatory drugs (NSAIDs, corticosteroids) is conceivable, but no specific drug–nutrient interaction studies have been published for ethyl linoleate. Similarly, its role as a lipid excipient in SMEDDS formulations means it may enhance the bioavailability of co-administered lipophilic compounds, which could theoretically alter the absorption of drugs taken concurrently. No clinical interaction data exist at this time.

Regulatory Classification

Ethyl linoleate is classified as a fatty acid alkyl ester used in the vitamin industry. It can be used in cosmetics. It appears in the INCI (International Nomenclature of Cosmetic Ingredients) dictionary under its standard name "Ethyl Linoleate." There is no current European Pharmacopoeia or USP monograph specifically for ethyl linoleate as a dietary supplement, nor has EFSA or the NIH Office of Dietary Supplements issued a formal evaluation of it as a standalone supplement ingredient.

Summary of Evidence Quality

The table below summarizes the quality and level of the available evidence for each principal area of use:

• Acne vulgaris (topical): One published RCT (combination product, British Journal of Dermatology, 2007) and one small pilot study (n=10, open-label, 2016). Moderate (limited by small sample sizes and combination-product designs).
• Melanogenesis / hyperpigmentation: In vitro studies only (murine and human cell lines). Preliminary; no human clinical data.
• Anti-inflammatory (systemic): In vitro mechanistic studies (RAW 264.7 macrophages). Preliminary; no dedicated human clinical data.
• Rheumatoid arthritis: Network pharmacology + in vivo rat model (collagen-induced arthritis, 2025). Very preliminary; indirect evidence only.
• Atherosclerosis / cardiovascular: Rodent studies (1960s–2014). Preliminary; no human clinical trials.
• Essential fatty acid delivery: Mechanistically well-established in animal research; clinical data extrapolated from the broader linoleic acid literature rather than ELA-specific trials.

References

• PubChem CID 5282184 — Ethyl Linoleate (NIH/NLM)
• Park SY et al. (2014). Ethyl linoleate from garlic attenuates lipopolysaccharide-induced pro-inflammatory cytokine production by inducing heme oxygenase-1 in RAW264.7 cells. International Immunopharmacology, 19(2):253–261.
• Ko GA et al. (2018). Ethyl linoleate inhibits α-MSH-induced melanogenesis through Akt/GSK3β/β-catenin signal pathway. Korean Journal of Physiology and Pharmacology, 22(1):53–61. (PMC5746512)
• Ko GA et al. (2018). Ethyl linoleate inhibits α-MSH-induced melanogenesis through Akt/GSK3β/β-catenin signal pathway. PubMed PMID 29302212.
• Charakida A, Charakida M, Chu AC. (2007). Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris. British Journal of Dermatology, 157(3):569–574.
• Huang X, Zhao Y, Hou Z. (2021). Purification of Ethyl Linoleate from Foxtail Millet (Setaria italica) Bran Oil via Urea Complexation and Molecular Distillation. Foods, 10(8):1925. (PMC8392090)
• Jiang et al. (2025). Ethyl Linoleate Ameliorates Synovial Cell Proliferation and Inflammatory Cell Infiltration in Rheumatoid Arthritis Through DKK1/Wnt-OPG Signal Axis and Autophagy. Drug Development Research.
• Drée T et al. (1984). Extremely decreased release of prostaglandin E2-like activity from chopped lung of ethyl linolenate-supplemented rats. PubMed PMID 6581373.
• Reduction of atherogenicity of natural fats by small additions of ethyl linoleate in the diet of the rat. PubMed PMID 17805763.
• Arreola R et al. (2015). Immunomodulation and Anti-Inflammatory Effects of Garlic Compounds. Journal of Immunology Research. PMC4417560.
• Batiha GES et al. (2022). Traditional uses, phytochemistry, pharmacology and toxicology of garlic (Allium sativum). Frontiers in Nutrition, 9:929554.
• Chaudhuri R. (2016). When Acne Attacks, Hexylresorcinol and Ethyl Linoleate Fight Back: Experimental (Part II). Cosmetics & Toiletries.
• Metabolism of Linoleic Acid in Relation to Dietary Saturated Fatty Acids in the Rat. Journal of Nutrition. ScienceDirect.
• Altintas A et al. (2006). Composition of the essential oils of Lycium barbarum and L. ruthenicum fruits. Chemistry of Natural Compounds, 42:24–25.
• Koo HJ et al. (2014). Chinese Yam Extracts Containing β-Sitosterol and Ethyl Linoleate Protect against Atherosclerosis in Apolipoprotein E-Deficient Mice and Inhibit Muscular Expression of VCAM-1 In Vitro. Journal of Food Science, 79:H719.